What is the market's earnings forecast for Rockwell Medical next quarter?

Did Rockwell Medical beat or miss consensus estimates last quarter?

What were the key takeaways from Rockwell Medical’s earnings call?

What does Rockwell Medical do and what are its main business segments?

What guidance did Rockwell Medical's management provide for the next earnings period?

What factors drove the changes in Rockwell Medical's revenue and profit?

What is the revenue and EPS growth rate for Rockwell Medical year over year?

What is Rockwell Medical's latest dividend and current dividend yield?

- **Record Q4 Performance**: 21% gross margin and $1M Adjusted EBITDA, ending 2025 with $25M cash.\n- **Customer Growth**: 30 new West Coast customers and expanding relationships with top dialysis providers.\n- **2026 Guidance**: Projected profitability with $1M-$2M Adjusted EBITDA and positive cash flow.\n- **Long-Term Ambition**: $100M+ sales by 2029, 30%+ gross margins, and $5M-$10M annual profitability through product diversification.

**【CEO Summary Section】**
- **2025 Performance Overview**: Navigated customer base and distribution changes, maintaining profitability with Adjusted EBITDA positive for the second consecutive year. Q4 2025 saw record gross margin and positive cash flow, ending the year with $25M in cash.
- **Customer Diversification**: Serves 300+ U.S. customers, including top dialysis providers (Fresenius, DaVita, IRC, DCI, Concerto), and 30+ international markets. Added 30 West Coast customers due to supply chain disruption, introducing a new bicarbonate cartridge expected to generate $1M in 2026 sales.
- **Operational Efficiency**: Appointed VP of Manufacturing, Rashad Brown, driving efficiency improvements. Gross margin expansion driven by pricing discipline, operational efficiencies, and stable production. 2026 guidance includes Adjusted EBITDA of $1M-$2M and positive cash flow.
- **Long-Term Vision**: Aims for $100M+ annual sales by 2029, gross margins in the 30% range, and $5M-$10M annual profitability through product diversification and innovation.

**【CFO Financial Commentary】**
- **Q4 2025 Results**: Net sales $18.3M (15% QoQ increase, 26% YoY decrease). Gross margin 21%, one of highest in company history. Adjusted EBITDA $1M (Q4) and $300K (full year). Cash increased to $25M, up $3.4M YoY.
- **2026 Outlook**: Projected profitability with positive operating cash flow, supported by margin expansion and working capital management.

**【Q&A Highlights】**
- **DaVita Relationship**: 2026 volumes expected to align with Q4 2025 levels, with potential for expansion based on performance. Competitors (Fresenius, Nipro) face challenges in quality and cost, reinforcing Rockwell's competitive advantage.
- **West Coast Expansion**: Actively pursuing additional customers, leveraging partnerships like B. Braun for regional growth.
- **At-Home Dialysis**: 10% market share, well-positioned for growth with adaptable product configurations. Exploring high-margin product acquisitions to diversify portfolio and boost profitability.

Rockwell Medical Inc (RMTI) Q4 2025 Earnings Call Transcript

- **Profitability milestone**: Q3 2025 adjusted EBITDA turned positive ($50K vs. -$200K Q2). 
- **Customer diversification**: Reduced reliance on largest customer to 12% of sales (from prior dominance). 
- **Cash strength**: $23.7M cash (34% QoQ increase) fuels 2026 M&A and growth initiatives. 
- **High-margin growth**: Bicarbonate cartridge adoption could add $1M+ annually, home dialysis market poised for 10-15% penetration. 
- **Operational efficiency**: 2025 restructuring saves $1.2M+ through plant closures and labor optimization.

**【CEO Summary Section】**
- Rockwell Medical achieved profitability on an adjusted EBITDA basis in Q3 2025, with $50,000 compared to negative $200,000 in Q2. 
- Despite a 44% YoY decline in net sales to $15.9 million due to the largest customer transition, gross margin stabilized at 14% (18% excluding restructuring costs). 
- Secured new contracts including a 3-year $1M+ annualized deal in Florida and expanded agreement with the largest dialysis provider, reducing reliance on any single customer to 12% of Q3 sales. 
- Bicarbonate cartridge launch is driving high-margin growth, with major customer adoption expected to accelerate in 2026. 
- West Coast expansion and home dialysis market (currently single-digit penetration) are key growth areas.

**【CFO Financial Commentary】**
- Cash position strengthened to $23.7 million (up 34% QoQ) from stock issuance and asset acquisition. 
- 2026 guidance expected in Q1 2026, with focus on labor cost efficiency and facility closures (e.g., $1.2M savings from plant consolidation). 
- Gross margin improved sequentially to 18% (non-restructured basis), with EBITDA trending positive despite 34% YoY revenue decline. 
- Acquisitions and customer base expansions are priorities for 2026 growth.

**【Q&A Key Highlights】**
- Largest customer transition expected to resolve in Q4 2025, with Rockwell maintaining 12% sales contribution despite supplier recall challenges. 
- 2026 guidance will include acquisitions and customer base expansions, targeting labor and distribution cost reductions. 
- Home dialysis market potential at 10-15% of total, with Rockwell's new product configurations driving higher-margin opportunities. 
- West Coast expansion plans include facility consideration for critical mass of new customers.

Rockwell Medical, Inc. (RMTI) Q3 2025 Earnings Call Transcript

- **Revenue Impact**: Q2 sales down 38% YoY due to largest customer loss, but stable 16% gross margin reflects cost management.
- **Diversification Success**: 80% of revenue now from long-term contracts, reducing concentration risk to <10% from largest customer.
- **Growth Opportunities**: $100M Western US expansion and potential Q4 upside from DaVita deal.
- **Financial Resilience**: Positive cash flow ($1.8M) and stable margins despite revenue decline, positioning for 2026 predictability.
- **Strategic Focus**: Automation investments and customer acquisition driving future efficiency and growth.

**【CEO Opening Remarks】**
- **Transition Year Progress**: Despite losing a major customer, Rockwell maintained stability with Q2 cash flow positive from operations and gross margin consistent at 16%.
- **New Contracts**: Secured multimillion-dollar agreements with IRC (3-year), a rural health system (2-year), and South Florida providers, reducing reliance on a single customer.
- **Customer Concentration Mitigation**: 80% of customers now on long-term contracts, down from 40-45% previously, with largest customer now contributing <10% of revenue.
- **2025 Guidance**: Reiterated net sales $65-70M, gross margin 16-18%, and adjusted EBITDA -$500k to +$500k.

**【CFO Financial Commentary】**
- **Revenue Decline**: Q2 net sales $16.1M (-38% YoY) due to largest customer transition, with H1 2025 sales $35M (-28% YoY).
- **Gross Profit**: Q2 gross profit $2.5M (-45% YoY), H1 $5.5M (-27% YoY), with stable 16% gross margin.
- **EBITDA**: Q2 adjusted EBITDA -$200k (improvement from Q1 -$400k), H1 -$700k vs. +$900k YoY.
- **Cash Position**: $18.4M at end of Q2 (+$1.8M from operations).

**【Q&A Highlights】**
- **Western US Expansion**: Targeting $100M opportunity with DaVita and Fresenius; expects clarity post Q3 negotiations.
- **DaVita Negotiations**: Optimistic for long-term supply agreement; potential Q4 financial impact if finalized.
- **Capital Allocation**: Prioritizing automation investments (e.g., manufacturing efficiency) and new customer acquisition over debt repayment.
- **Gross Margin Stability**: Achieved via staff reductions, equipment upgrades, and minimal margin contribution from largest customer.
- **Competitor Recall Impact**: Supplemented competitor's supply during recall, reinforcing Rockwell's reliability in critical patient care.


Rockwell Medical, Inc. (RMTI) Q2 2025 Earnings Call Transcript

- **Revenue decline driven by customer loss**: Q1 2025 net sales down 17% to $18.9M due to largest customer transition. 
- **Gross margin improvement**: 16% in Q1 2025 (vs. 14% YoY) from cost optimization. 
- **New product opportunity**: Bicarbonate cartridge launch in Feb 2025 targeting high-growth dialysis segment. 
- **Q2 expected to be trough**: CFO projects Q2 as weakest quarter with recovery in H2. 
- **Latin America growth engine**: International expansion focused on emerging dialysis centers. 


**【CEO Summary Section】**
- **Q1 2025 Performance**: Revenue of $18.9M (-17% YoY) due to largest customer transitioning to a competitor. Gross margin improved to 16% (vs. 14% in Q1 2024). 
- **Customer Diversification**: Signed new contracts with regional/national dialysis providers; 90% of revenue remains U.S.-based. 
- **New Product Launch**: Bicarbonate cartridge launched in Feb 2025, targeting fastest-growing dialysis segment. 
- **2025 Guidance**: Net sales $65-70M, gross margin 16-18%, adjusted EBITDA (-$0.5M to +$0.5M). 
- **Cybersecurity Update**: No impact from recent industry ransomware attack; systems disconnected proactively. 
- **Tariff Impact**: Minimal (1% of revenue) as 90% of products manufactured in U.S. 

**【CFO Financial Commentary】**
- **Net Loss**: $1.5M (vs. $1.7M YoY), driven by $900K one-time payment from largest customer. 
- **Cash Position**: $17.3M (down from $21.6M at year-end due to seasonal expenses). 
- **Adjusted EBITDA**: -$0.4M (sequential improvement from -$0.5M in Q4 2024). 

**【Q&A Key Highlights】**
- **Largest Customer Negotiations**: Discussions for scaled-down agreement to replenish safety stock; no timeline for resolution. 
- **Revenue Cadence**: Q2 likely weakest quarter; Q3+ growth driven by new customer wins. 
- **At-Home Dialysis**: High-margin product seeing early traction; expects meaningful contribution in H2 2025. 
- **West Coast Expansion**: Exploring facility in West to serve underpenetrated market; no decision yet. 
- **Latin America Growth**: Emerging dialysis centers driving international expansion. 


Rockwell Medical (RMTI)-12 May 25-2025 Q1 Earnings call transcript

- **2024 Milestone Achievement**: $101.5M net sales, 17% gross margin, and first full-year adjusted EBITDA profitability.
- **2025 Transition Plan**: $65-70M net sales guidance due to $34M loss from largest customer transition; targeting 16-18% gross margin.
- **Growth Drivers**: New products (bicarbonate cartridges, convenience packs), international expansion (30+ countries), and cost reductions ($2+M annually).
- **Financial Strength**: $21.6M cash balance, reduced net loss, and strong balance sheet for 2025 execution.

**【CEO Summary Section】**
- Achieved full-year 2024 net sales of $101.5 million, gross margin of 17%, and first-time full-year adjusted EBITDA profitability.
- Largest customer will transition away by June 30, 2025, resulting in $34 million revenue loss compared to 2024.
- 2025 guidance: $65-70 million net sales, 16-18% gross margin, and adjusted EBITDA near breakeven.
- Focus on diversifying customer base, product portfolio, and cost optimization.

**【CFO Financial Commentary】**
- Q4 2024 net sales: $24.7 million (12% YoY growth); full-year 2024: $101.5 million (21% YoY growth).
- Gross profit improved to $17.5 million (vs. $8.7 million in 2023), driven by price increases and cost reductions.
- Net loss reduced to $500,000 (vs. $8.4 million in 2023); adjusted EBITDA: $5.2 million (vs. -$3.9 million in 2023).
- Cash balance: $21.6 million at year-end, up from $10.9 million in 2023.

**【Commercial Strategy Highlights】**
- Expanded into new markets with convenience packs, single-use bicarbonate cartridges, and international agreements (e.g., Nephro Group in Philippines).
- Signed $10 million+ product purchase agreement with leading dialysis provider and distribution deal with Nipro Medical for global expansion.
- Targeting 14.5 million gallons of potential US business and $100 million opportunity in single-use bicarbonate cartridges.

**【Q&A Highlights】**
- Largest customer transition: discussions ongoing for potential future agreements, but no impact on 2025 guidance.
- 2025 strategy: replace lost revenue with new customers, reduce expenses by $2+ million annually, and focus on high-margin international sales.
- Bicarbonate cartridge growth: targeting existing customers first, with long-term potential in machine-compatible cartridge adoption.
- West Coast expansion: exploring dedicated facilities as sales grow, leveraging current distribution network.


Actual											-1.32	-1.1	-1.1	-0.99	-0.88	-0.99	-0.88	-1.1	-0.84	-0.56	-0.4	-0.2	-0.1	-0.18	-0.07	-0.05	-0.06	0.01	0.05	-0.02	-0.04	-0.05	-0.05	-0.01
Forecast											-1.43	-1.54	-1.1	-0.935	-0.99	-0.88	-0.825	-0.99	-0.99	-0.81	-0.485	-0.39	-0.165	-0.12	-0.105	-0.07	-0.04	-0.035	0.01	0.0033	-0.05	-0.05	-0.045	0.02
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+7.69%	+28.57%	0.00%	-5.88%	+11.11%	-12.50%	-6.67%	-11.11%	+15.15%	+30.86%	+17.53%	+48.72%	+39.39%	-50.00%	+33.33%	+28.57%	-50.00%	+128.57%	+400.00%	-706.06%	+20.00%	0.00%	-11.11%	-150.00%

Actual	--	--	--	--	--	--	--	--	--	--	15.86M	15.90M	15.28M	15.16M	15.47M	15.14M	15.99M	15.30M	16.12M	18.68M	18.70M	19.31M	19.67M	18.08M	23.77M	22.09M	22.68M	25.80M	28.30M	24.66M	18.91M	16.07M	15.93M	18.34M
Forecast	--	--	--	--	--	--	--	--	--	--	15.55M	14.41M	15.67M	15.66M	17.24M	18.22M	18.18M	17.65M	18.80M	16.80M	19.37M	16.30M	19.12M	18.08M	22.85M	22.63M	21.70M	22.91M	26.50M	23.50M	17.46M	16.33M	16.24M	18.60M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+1.99%	+10.34%	-2.50%	-3.16%	-10.25%	-16.90%	-12.05%	-13.32%	-14.23%	+11.20%	-3.46%	+18.48%	+2.88%	+0.02%	+4.05%	-2.39%	+4.48%	+12.59%	+6.82%	+4.95%	+8.33%	-1.60%	-1.93%	-1.37%

RMTI

RMTI fundamentals

RMTI Q4 2025 Earnings

Earnings Call

You can ask Aime

RMTI

RMTI fundamentals

RMTI Q4 2025 Earnings

Earnings Call

RMTI Earnings Call Summary for Q4/2025Today8:00 AM on Mar 26, 2026

RMTI Earnings Call Summary for Q3/20258:00 AM on Nov 12, 2025

RMTI Earnings Call Summary for Q2/20258:00 AM on Aug 14, 2025

RMTI Earnings Call Summary for Q1/20258:00 AM on May 12, 2025

RMTI Earnings Call Summary for Q4/20248:00 AM on Mar 20, 2025

You can ask Aime